BRAF and melanoma: Finally, a population-based study in 912 patients with primary cutaneous melanoma from the United States and Australia found that melanoma-specific survival was significantly poorer for higher risk (T2b or higher) tumors with a BRAF (HR=3.1, 95% CI 1.2–8.5) mutation but not for lower risk tumors24.